TUCSON, Ariz. , Feb. 07, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that management will present in a fireside chat at the LEERINK Partners 7th Annual Global…
TUCSON, Ariz. , Jan. 18, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced the pricing of an underwritten public offering of 12,100,000 shares of its common stock at a…
TUCSON, Ariz. , Jan. 16, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced that it intends to offer and sell, subject to market and other conditions, 10,000,000 shares…
TUCSON, Ariz. , Jan. 16, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today announced it has entered into a third statement of work for a new clinical assay development program…
Join HTG at the 2018 SFCO Conference and learn more about our NGS-based sequencing assays that are automated on the HTG EdgeSeq system.
Palais Des Congres | Atlantia, FR | March 29 - March 31, 2018
Join HTG at the Molecular Pathology in Oncology at stand 7 and learn more about our HTG EdgeSeq PATH Assay. The assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry testing by allowing investigators to assess mRNA expression of large numbers of markers when tissue availability is limited.
Biomedical Research Centre | The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research | London, UK | March 15, 2018
Fourth quarter 2017 revenue expected to be between $6.9 and $7.2 million Full year 2017 revenue expected to be between $13.8 and $14.1 million Initial full year 2018 revenue guidance of $20.0 to $25.0 million TUCSON, Ariz. , Jan. 04, 2018 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc….
Signs Master Collaboration Agreement for Assay Development and Manufacturing of Kits Supporting Biomarker Research Programs TUCSON, Ariz. and DARMSTADT, Germany , Dec. 26, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for…
TUCSON, Ariz. , Dec. 20, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (NASDAQ:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that its senior management team will host institutional investor and partnering meetings at the…
Revenue increased 307% and 87%, respectively, compared to the three and nine month periods in the prior year driven by development efforts supporting Pharma clinical programs TUCSON, Ariz. , Nov. 07, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc….
TUCSON, Ariz., Oct. 20, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will report its financial results for the three and nine months ended September 30, 2017 after the market close on Tuesday, November 7th. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
Page last updated March 20, 2023